Utility of short-form headache impact test (HIT-6) to quantify the benefits of stratified care in migraine

被引：0
|
作者：
Mateos, V [1 ]
机构：
[1] Univ Oviedo, Hosp Cent Asturias, Dept Neurol, E-33080 Oviedo, Spain
来源：
CEPHALALGIA | 2005年 / 25卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：668 / 668
页数：1
相关论文
共 40 条
  • [31] Evaluation of Relationship Between Sleep Bruxism and Headache Impact Test-6 (HIT-6) Scores: A Polysomnographic Study
    Martynowicz, Helena
    Smardz, Joanna
    Michalek-Zrabkowska, Monika
    Gac, Pawel
    Poreba, Rata
    Wojakowska, Anna
    Mazur, Gtzegorz
    Wieckiewicz, Mieszko
    FRONTIERS IN NEUROLOGY, 2019, 10
  • [32] Recognition and management of migraine in primary care: influence of functional impact measured by the headache impact test (HIT)
    De Diego, EV
    Lanteri-Minet, M
    CEPHALALGIA, 2005, 25 (03) : 184 - 190
  • [33] Headache-related disability measured with Headache impact test-6 (HIT-6) Results from an Estonian population-based survey
    Vaikjarv, M.
    Braschinsky, K.
    Raidvee, A.
    Braschinsky, M.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [34] Measuring health-related quality of life in chronic headache: A comparative evaluation of the Chronic Headache Quality of Life Questionnaire and Headache Impact Test (HIT-6)
    Haywood, Kirstie L.
    Achana, Felix
    Nichols, Vivien
    Pearce, Gemma
    Box, Barbara
    Muldoon, Lynne
    Patel, Shilpa
    Griffiths, Frances
    Stewart, Kimberly
    Underwood, Martin
    Matharu, Manjit M.
    CEPHALALGIA, 2021, 41 (10) : 1100 - 1123
  • [35] Medical consultation and headache-impact (hit-6) among persons with chronic migraine (cm) and episodic migraine (em): results from the american migraine prevalence and prevention (ampp) study
    Manack, A. N.
    Buse, D. C.
    Serrano, D.
    Varon, S. F.
    Turkel, C. C.
    Lipton, R. B.
    CEPHALALGIA, 2011, 31 (01) : 29 - 29
  • [36] Knowledge and management of migraine in primary care:: Influence of functional impairment appreciated by Headache Impact Test (HIT) score
    de Diego, ED
    Lantéri-Minet, M
    CEPHALALGIA, 2003, 23 (07) : 601 - 601
  • [37] Reductions in headache impact test (HIT-6) scores with fremanezumab and erenumab among patients with episodic migraine (EM) and 2-4 prior treatment failures: A network meta-analysis
    Pozo-Rosich, P.
    Patterson-Lomba, O.
    Mu, F.
    Thompson, S.
    Gandhi, S.
    Doctor, T.
    Bousleiman, S.
    Yang, R.
    Cohen, J. M.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [38] Effects of Atogepant as Evaluated by the Activity Impairment in Migraine-Diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 158 - 158
  • [39] Effects of Atogepant as Evaluated by the Activity Impairment in Migraine-Diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-Week, Double-blind, Randomized Phase 3 (ADVANCE) Trial for Preventive Treatment of Migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 106 - 106
  • [40] Effects of atogepant as evaluated by the activity impairment in migraine-diary (AIM-D) and Headache Impact Test (HIT-6) in a 12-week, double-blind, randomized phase 3 (ADVANCE) trial for preventive treatment of migraine
    Lipton, R. B.
    Pozo-Rosich, P.
    Blumenfeld, A. M.
    Li, Y.
    Severt, L.
    Stokes, J.
    Gandhi, P.
    Dodick, D. W.
    HEADACHE, 2021, 61 : 46 - 47
1234